PharmaShots conducted its fourth “Spotlight- Company of the Month with TAE Life Sciences”. In conversation with Bruce Bauer (CEO) & Kendall Morrison (CSO) at TAE Life Sciences, they both shared insights on TAE Life Sciences’ vision, upcoming plans, technologies used, and developing products. Bruce and Kendall spoke about TAE’s novel treatment options which could potentially improve the lives of cancer patients.
TAE Life Sciences is a clinical-stage biotech that spun out from TAE Technologies in 2017 with a focus to develop and commercialize a breakthrough biologically targeted radiation treatment for the most difficult cancers. TAE Life Sciences’ Alphabeam™ neutron system is compact and practical for installation in a hospital setting. TAE Life Science has made a significant investment in developing a portfolio of new Boron-10 target drugs to expand the application of BNCT to new cancer types.
About the Speakers:
Bruce Bauer
Bruce Bauer is the CEO at TAE Life Sciences. He organized the founding of TAE Life Sciences with technology licensed from TAE Technologies. Bruce is an active investor and entrepreneur. He has spun out technology into new companies, developed products for international markets, and built management teams with cross-border operations. Following a career in the medical imaging industry, Bruce entered the private equity industry, ultimately founding Newbury Ventures and spending decades in international venture capital focused on healthcare, imaging, sensors, enterprise software, and industrial businesses. Bruce holds B.S.E. and Ph.D. degrees in Biomedical Engineering from Duke University.
Kendall Morrison
Kendall Morrison is the CSO at TAE Life Sciences. Dr. Morrison is a noted expert in antibody development and biotechnology. He has over 30 years of experience developing breakthrough technologies for the treatment, diagnosis, and study of immunological and oncological conditions. He has played a significant role in the development of Certolizumab pegol (trade name Cimzia), which is currently approved for the treatment of Crohn’s disease, rheumatoid arthritis psoriatic arthritis, and ankylosing spondylitis. He is a member of the British Society of Immunology and has published influential papers in Molecular Cancer Therapeutics, Cancer Research, the American Journal of Pathology, the Journal of Clinical Pathology, and more. He holds a combined B.S. with honors in Microbiology and Immunology from the University of West Scotland, UK; and a Ph.D. in Pathology and Molecular Biology from the Medical School at the University of Southampton, UK.
Related Post: Spotlight Interview with Rohan (Ro) F. Hastie, President & CEO at Metabolon